Patients with ovarian cancer showed significantly higher serum levels of pro-inflammatory interleukins (IL-1α, IL-1β, IL-18, IL-33, IL-36α), anti-inflammatory interleukin (IL-37) and interleukins with antagonistic properties (IL-1Ra, IL-36Ra, IL-38), indicating a regulatory mechanism of these interleukins in the process of ovarian cancer development. This evidence concerns the gene IL1A and ovarian cancer.